Videos

Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

The panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.

Ritu Salani, MD, suggests using the immune system to find treatment options for cervical cancer is the logical course of action.

More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.

An expert on acute myeloid leukemia gives an overview of disease subtypes and provides insights on risk stratification.

Ghayas C. Issa, MD, describes the typical presentation of patients with acute myeloid leukemia and provides clinical insights on evaluating response and potential disease progression.

Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.

The phase 3 NRG GY018 trial added immunotherapy to chemotherapy in patients with recurrent endometrial cancer, regardless of mismatch repair deficient or proficient disease status, according to Ramez N. Eskander, MD.

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Highlight on the debate format, speakers, and direction to support the discussion.

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

An outline of the debate, the speakers, and the basic guidelines to support the program.

Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.

Dr Narjust Florez outlines FDA-approved firstline therapy options for KRAS G12C mutated non-small cell lung cancer, and notes most patients progress and require second line targeted therapy.

Narjust Florez, MD, discusses KRAS G12C mutated non-small cell lung cancer, a subset of KRAS mutations which comprises 14% of NSCLC cases.

Experts discuss the strategies and considerations for bridging therapy and the management of patients with relapsed/refractory multiple myeloma receiving CAR T-cell therapy.

After his initial fear, Mr. Fuentes educated himself extensively on cancer to understand his diagnosis, which along with having a treatment plan in place, specialist referrals, and tolerable side effects, helps him maintain a positive mindset and manageable quality of life with stage 4 disease.

Luciano Costa, MD, discusses the effectiveness and challenges of CAR-T therapy ciltacabtagene autoleucel for patients with multiple myeloma, emphasizing the response rates and duration and the advantages in early lines of treatment.

Mr. Cesar Fuentes had a kidney tumor surgically removed; lymph node and bone metastases years later led to immune and targeted therapy which have provided significant tumor shrinkage and generally mild, manageable side effects.

The panel discusses the effect minimal residual disease (MRD) has on treatment selection and provides insights on the treatment of younger patients with standard risk.

Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.

Expert perspectives on the practical applications of consolidation and maintenance therapies for patients with multiple myeloma.

The expert panel provides an overview of relapsed/refractory multiple myeloma, with a focus on current therapeutic options and unmet needs in the treatment space.

Including minority populations in clinical trials can be most easily done through outreach and partnerships with other health centers, according to Adam B. Murphy, MD, MBA, MSCI.

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.

Dr Stacy A. Cohen discusses the DESTINY-CRC01 trial investigating trastuzumab deruxtecan in patients with colorectal cancer, specifically addressing the use of a targeted therapy for HER2 in colorectal cancer patients, highlighting the importance of prior therapy history and optimal dosage to balance efficacy and toxicity.

Tanios S. Bekaii-Saab, MD, presents the case of a 64-year-old woman with HER2+ colorectal cancer to the panel for discussion.

Leading experts discuss the evolving landscape of myeloma immunotherapy, highlighting the potential of CAR-T and bispecifics and emphasizing the need for effective management of related toxicities to enhance patient outcomes.

Experts on colorectal cancer provide their key takeaways from the results from the SUNLIGHT study.